JP2017536119A5 - - Google Patents

Download PDF

Info

Publication number
JP2017536119A5
JP2017536119A5 JP2017526918A JP2017526918A JP2017536119A5 JP 2017536119 A5 JP2017536119 A5 JP 2017536119A5 JP 2017526918 A JP2017526918 A JP 2017526918A JP 2017526918 A JP2017526918 A JP 2017526918A JP 2017536119 A5 JP2017536119 A5 JP 2017536119A5
Authority
JP
Japan
Prior art keywords
lna
nucleosides
oligonucleotide according
nucleoside
phosphorothioate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017526918A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017536119A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/076967 external-priority patent/WO2016079181A1/en
Publication of JP2017536119A publication Critical patent/JP2017536119A/ja
Publication of JP2017536119A5 publication Critical patent/JP2017536119A5/ja
Pending legal-status Critical Current

Links

JP2017526918A 2014-11-19 2015-11-18 キラルホスホロチオエート連結を含むlnaギャップマーオリゴヌクレオチド Pending JP2017536119A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
EP14193887.8 2014-11-19
EP14193887 2014-11-19
EP14198167.0 2014-12-16
EP14198167 2014-12-16
EP15182401.8 2015-08-25
EP15182401 2015-08-25
EP15191076.7 2015-10-22
EP15191074 2015-10-22
EP15191075.9 2015-10-22
EP15191076 2015-10-22
EP15191075 2015-10-22
EP15191074.2 2015-10-22
PCT/EP2015/076967 WO2016079181A1 (en) 2014-11-19 2015-11-18 Lna gapmer oligonucleotides comprising chiral phosphorothioate linkages

Publications (2)

Publication Number Publication Date
JP2017536119A JP2017536119A (ja) 2017-12-07
JP2017536119A5 true JP2017536119A5 (enExample) 2018-11-15

Family

ID=54608516

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017526918A Pending JP2017536119A (ja) 2014-11-19 2015-11-18 キラルホスホロチオエート連結を含むlnaギャップマーオリゴヌクレオチド
JP2017526905A Pending JP2017536366A (ja) 2014-11-19 2015-11-18 Lnaキラルホスホロチオエート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017526905A Pending JP2017536366A (ja) 2014-11-19 2015-11-18 Lnaキラルホスホロチオエート

Country Status (4)

Country Link
US (2) US20180112217A1 (enExample)
EP (2) EP3221329A1 (enExample)
JP (2) JP2017536119A (enExample)
WO (2) WO2016079183A1 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394333B2 (en) 2008-12-02 2016-07-19 Wave Life Sciences Japan Method for the synthesis of phosphorus atom modified nucleic acids
MX342945B (es) 2009-07-06 2016-10-18 Ontorii Inc * Profármacos de ácido nucleico novedosos y métodos de uso de los mismos.
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
KR20240148947A (ko) 2012-07-13 2024-10-11 웨이브 라이프 사이언시스 리미티드 키랄 제어
SG11201500243WA (en) 2012-07-13 2015-04-29 Shin Nippon Biomedical Lab Ltd Chiral nucleic acid adjuvant
SG11201500239VA (en) 2012-07-13 2015-03-30 Wave Life Sciences Japan Asymmetric auxiliary group
US11162096B2 (en) 2013-10-14 2021-11-02 Ionis Pharmaceuticals, Inc Methods for modulating expression of C9ORF72 antisense transcript
EP3095460A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
ES2917473T3 (es) 2014-01-16 2022-07-08 Wave Life Sciences Ltd Diseño quiral
CA2968336C (en) 2014-12-17 2021-11-23 Proqr Therapeutics Ii B.V. Construct for site directed editing of an adenosine nucleotide in target rna
US10793855B2 (en) * 2015-01-06 2020-10-06 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of C9ORF72 antisense transcript
WO2016167780A1 (en) 2015-04-16 2016-10-20 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
CN108025089A (zh) 2015-07-22 2018-05-11 波涛生命科学有限公司 寡核苷酸组合物及其方法
WO2017067970A1 (en) 2015-10-22 2017-04-27 Roche Innovation Center Copenhagen A/S In vitro toxicity screening assay
US11267843B2 (en) * 2016-03-18 2022-03-08 Roche Innovation Center Copenhagen A/S Stereodefining L-monomers
CN109477108A (zh) 2016-05-04 2019-03-15 波涛生命科学有限公司 寡核苷酸组合物和其方法
US11479818B2 (en) * 2016-06-17 2022-10-25 Hoffmann-La Roche Inc. In vitro nephrotoxicity screening assay
EP3472346B1 (en) 2016-06-17 2023-01-18 F. Hoffmann-La Roche AG Papd5 and papd7 inhibitors for treating a hepatitis b infection
WO2017216340A1 (en) * 2016-06-17 2017-12-21 F. Hoffmann-La Roche Ag In vitro nephrotoxicity screening assay
CN109477103A (zh) 2016-06-22 2019-03-15 ProQR治疗上市公司Ⅱ 单链rna-编辑寡核苷酸
EP3507366B1 (en) 2016-09-01 2020-10-07 ProQR Therapeutics II B.V. Chemically modified single-stranded rna-editing oligonucleotides
CN114621302A (zh) * 2016-11-14 2022-06-14 学校法人东京理科大学 聚合性化合物、化合物、及硼烷磷酸酯低聚物的制造方法
JP7296882B2 (ja) 2016-11-23 2023-06-23 ウェイブ ライフ サイエンシズ リミテッド ホスホラミダイト及びオリゴヌクレオチド合成のための組成物及び方法
WO2018130583A1 (en) * 2017-01-13 2018-07-19 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating nfkb1 expression
WO2018130585A1 (en) * 2017-01-13 2018-07-19 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating relb expression
EP3571300A1 (en) 2017-01-19 2019-11-27 ProQR Therapeutics II B.V. Oligonucleotide complexes for use in rna editing
EP3694995A1 (en) 2017-10-13 2020-08-19 Roche Innovation Center Copenhagen A/S Methods for identifying improved stereodefined phosphorothioate oligonucleotide variants of antisense oligonucleotides utilising sub-libraries of partially stereodefined oligonucleotides
TW202424191A (zh) * 2017-10-16 2024-06-16 瑞士商赫孚孟拉羅股份公司 用於降低PAPD5及PAPD7 mRNA以治療B型肝炎感染之核酸分子
HRP20250804T1 (hr) 2017-12-01 2025-09-12 The Texas A&M University System Antisense liječenje angelmanovog sindroma
US20200339982A1 (en) * 2017-12-22 2020-10-29 Roche Innovation Center Copenhagen A/S Oligonucleotides comprising a phosphorodithioate internucleoside linkage
KR20200104302A (ko) * 2017-12-22 2020-09-03 로슈 이노베이션 센터 코펜하겐 에이/에스 신규 티오포스포르아미다이트
KR20200104347A (ko) * 2017-12-22 2020-09-03 로슈 이노베이션 센터 코펜하겐 에이/에스 포스포로디티오에이트 인터뉴클레오시드 연결을 포함하는 갭머 올리고뉴클레오티드
MX2020007433A (es) 2018-01-12 2020-09-14 Bristol Myers Squibb Co Oligonucleotidos antisentido que actuan sobre alfa-sinucleina, y usos de estos.
EA202091693A1 (ru) 2018-01-12 2021-04-14 Бристол-Маерс Сквибб Компани Антисмысловые олигонуклеотиды, целенаправленно воздействующие на альфа-синуклеин, и их применения
EP3774824A1 (en) 2018-04-13 2021-02-17 Bristol-Myers Squibb Company Novel phosphorous (v)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (v) compounds
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
PE20220013A1 (es) 2018-07-03 2022-01-11 Hoffmann La Roche Oligonucleotidos para modular la expresion de tau
CN112469827B (zh) * 2018-07-04 2024-05-24 学校法人爱知医科大学 控制Tau的剪接的反义寡核苷酸及其用途
CN113490742A (zh) * 2019-02-20 2021-10-08 罗氏创新中心哥本哈根有限公司 膦酰基乙酸酯缺口聚物寡核苷酸
US11466274B2 (en) 2019-05-31 2022-10-11 Aligos Therapeutics, Inc. Modified gapmer oligonucleotides and methods of use
WO2021146391A1 (en) 2020-01-16 2021-07-22 Bristol-Myers Squibb Company Reagents and their use for modular enantiodivergent synthesis of c–p bonds
AU2022242781A1 (en) * 2021-03-26 2023-10-26 Neumirna Therapeutics Aps Microrna-27b inhibitors
CN120187734A (zh) 2022-09-19 2025-06-20 百时美施贵宝公司 新的基于磷(v)的试剂、其制备方法以及其在制备立体定义的有机磷(v)化合物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242589B1 (en) * 1998-07-14 2001-06-05 Isis Pharmaceuticals, Inc. Phosphorothioate oligonucleotides having modified internucleoside linkages
DK2092065T4 (da) * 2006-10-18 2019-10-21 Ionis Pharmaceuticals Inc Antisense-forbindelser
KR20240148947A (ko) * 2012-07-13 2024-10-11 웨이브 라이프 사이언시스 리미티드 키랄 제어
DK2951305T3 (en) * 2013-01-30 2018-10-29 Hoffmann La Roche LNA oligonucleotide KULHYDRATKONJUGATER

Similar Documents

Publication Publication Date Title
JP2017536119A5 (enExample)
JP2017536366A5 (enExample)
JP2020058368A5 (enExample)
JP2016116520A5 (enExample)
JP2018512110A5 (enExample)
JP2020022483A5 (enExample)
HRP20241138T1 (hr) Oligonukleotidi za induciranje ekspresije očinskog ube3a
JP2018512041A5 (enExample)
JP2013226147A5 (enExample)
JP2020532961A5 (enExample)
JP2017505623A5 (enExample)
JP2012510297A5 (enExample)
JP2013511990A5 (enExample)
JP2021505129A5 (enExample)
HRP20210315T1 (hr) Oligonukleotidi za smanjenje ekspresije pd-l1
JP2009524419A5 (enExample)
JP2016530294A5 (enExample)
JP2016171800A5 (enExample)
JP2013535212A5 (enExample)
JP2016513976A5 (enExample)
JP2012105686A5 (enExample)
JP2018531037A5 (enExample)
JP2009532044A5 (enExample)
JP2016520310A5 (enExample)
JP2015517806A5 (enExample)